Abbott Laboratories (NYSE:ABT) manufacturer of health care products, is expected to report third quarter earnings results, before market open, on Wednesday 21st October 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.90 per share.
Looking ahead, the full year income are expected at $ 3.32 per share on the revenues of $ 33203.90 million.
The Company Outlook
Full Year 2020 bottomline are predicted in a range of $ 3.55 ~ $ 3.65 per share
Click Here For More Historical Outlooks Of Abbott Laboratories
Previous Quarter Performance
Abbott Laboratories communicated income for the second quarter of $ 0.57 per share, from the revenue of $ 7,328.00 million. The quarterly earnings 30.49 percent while revenues reduced 8.16 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.41 per share from $ 6749.42 million in revenue. The bottom line results beat street analysts by $ 0.16 or 39.02 percent, at the same time, top line results outshined analysts by $ 578.58 million or 8.57 percent.
Stock Performance
Shares of Abbott Laboratories traded up $ 0.39 or 0.36 percent on Tuesday, reaching $ 108.43 with volume of 3.38 million shares. Abbott Laboratories has traded high as $ 109.88 and has cracked $ 108.11 on the downward trend
The closing price of $ 108.43, representing a 75.36 % increase from the 52 week low of $ 61.61 and a 5.39 % decrease over the 52 week high of $ 114.20.
The company has a market capital of $ 191.97 billion and is part of the Healthcare sector and Medical Appliances & Equipment industry.
Recent Analyst recommendations
- On 11th September 2020, initiated by Wolfe Research at Outperform rating, with $ 124.00 target price.
- On 31st August 2020, maintained by Credit Suisse Group at Outperform rating, with $ 136.00 target price.
- On 27th August 2020, maintained by Morgan Stanley at Overweight rating, with $ 112.00 target price.
Conference Call
Abbott Laboratories will be hosting a conference call at 9:00 AM eastern time on 21st October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.abbott.com
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The companys Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménières disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.
